
AI discontinuation common among breast cancer patients
Nearly a third of early-stage breast cancer patients stop their aromatase inhibitor treatment early because of intolerance, although when offered an alternative AI medication, over a third are able to continue.
6 days ago

Patients want greater role in breast cancer treatment
Two-thirds of women with early-stage breast cancer want to be involved in planning their treatment, although just under half say their doctor ultimately made the decision, an Australian-funded study reports.
6 days ago